Thu, November 18, 2010
Wed, November 17, 2010
Tue, November 16, 2010
Mon, November 15, 2010
Sun, November 14, 2010
Fri, November 12, 2010
Thu, November 11, 2010
Wed, November 10, 2010
Tue, November 9, 2010
Mon, November 8, 2010
Sun, November 7, 2010
Sat, November 6, 2010
Fri, November 5, 2010
Thu, November 4, 2010
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010

Teva to Present at the Credit Suisse 2010 Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. he-credit-suisse-2010-healthcare-conference.html
Published in Health and Fitness on Tuesday, November 9th 2010 at 13:35 GMT by Market Wire   Print publication without navigation


JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Credit Suisse 2010 Healthcare Conference with William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Thursday, November 11, 2010.

What: Teva Presentation at the Credit Suisse 2010 Healthcare Conference
Who: William Marth, President & CEO, Teva Pharmaceuticals a" Americas
When: Thursday, November 11, 2010 at 4:00pm EST
Where:

[ www.tevapharm.com/financial/ ] or

[ http://cc.talkpoint.com/cred001/111010a_rb/?entity=8_8QY65MI ]

How: Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.


Publication Contributing Sources